Skip to main content
Clinical Trials/NL-OMON41067
NL-OMON41067
Completed
Phase 2

Dexmedetomidine in awake implantation of neuromodulative systems. - DexMed

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Awake implantation of a neuromodulative system.
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Patients need to be between 18 and 65 years.;\- Patients have an indication for implantation of a neuromodulative system.

Exclusion Criteria

  • \- Hypersensitivity of active part of one of any of the excipients
  • \- AV\-block (II or III)
  • \- Acute cerebrovascular disease
  • \- Pregnancy
  • \- Acute epilepsy
  • \- Severe liver dysfunction
  • \- Use of a beta blocker.
  • \- Psychologically unstable
  • \- Communication problem.

Outcomes

Primary Outcomes

Not specified

Similar Trials